Navigation Links
Novel method for increasing antibiotic yields
Date:9/5/2011

A novel way of increasing the amounts of antibiotics produced by bacteria has been discovered that could markedly improve the yields of these important compounds in commercial production. It could also be valuable in helping to discover new compounds. With the ever-growing threat from antibiotic resistance, these tools will be very useful in ensuring that we have enough of these useful compounds in the future.

The majority of antibiotics we know of today are produced naturally by a group of soil bacteria called Streptomyces. For commercial production of these antibiotics for clinical use, it is necessary to increase the yield. This has typically been achieved by randomly inducing mutations and screening for strains that show increased production, a process that takes many years. When technology had progressed sufficiently to analyse how this had been achieved scientists found that, in some cases, the increase in yield was due to repeated copies of the genes needed for antibiotic production.

In almost all cases, the genes needed to produce these antibiotics are clustered together in the bacterial genome. In work carried out initially at the John Innes Centre, which is strategically funded by the Biotechnology and Biological Sciences Research Council, Professor Mervyn Bibb and collaborator Dr Koji Yanai from a Japanse laboratory discovered 36 repeating copies of one gene cluster in a strain of Streptomyces that had been repeatedly selected to over-produce the antibiotic kanamycin.

"This suggested to us that controlled and stable amplification of antibiotic gene clusters might be possible, and that if it was, it would be a valuable tool for engineering high yielding commercial strains of bacteria," said Prof Bibb. The researchers then went on to identify the components within Streptomyces responsible for creating the 36 repeating clusters that led to kanamycin overproduction. These consist of two DNA sequences that flank the gene cluster, and a
'/>"/>

Contact: Andrew Chapple
andrew.chapple@nbi.ac.uk
01-603-251-490
Norwich BioScience Institutes
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel method for increasing antibiotic yields
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... in how organisms grow and flourish, but studying their ... difficult. Now, a team of chemists and neurobiologists led ... Erin M. Schuman at the California Institute of Technology ... protein synthesis in specific locations. , The new method, ...
... at the University of Chicago show how the bacteria that ... how, by slightly altering one of the microbe's tools, the ... vaccine. , Both papers -- one published online July 28 ... Infection and Immunity -- focus on aspects of the type-III ...
... greatly benefit crop plants, scientists have deciphered the genome ... from diseases. , The research provides clues to better ... safeguards roots and seeds from infection by harmful microbes ... published in Nature Biotechnology and was scheduled to be ...
Cached Biology News:Protein synthesis can be controlled by light, opening way for new scientific, medical applications 2Protein synthesis can be controlled by light, opening way for new scientific, medical applications 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4Genome study of beneficial microbe may help boost plant health 2
(Date:5/26/2015)... 2015  Alere Inc. (NYSE: ALR ) (the "Company") ... timely file its Quarterly Report on Form 10-Q for the ... has received a notice from the New York Stock Exchange ... the NYSE,s continued listing requirements under the timely filing criteria ... The reason for the delay relates to ...
(Date:5/26/2015)... 2015   PDI , a leader in ... Oakwood Healthcare in Dearborn, Mich. ... in Delivering the Difference , ... in building collaborative relationships between infection prevention (IP) ... Oakwood Healthcare,s infection preventionist, ...
(Date:5/26/2015)... ANGELES , 26. mája 2015 ... v mene svojej rodiny prezidentom Barackovi Obamovi a ... v súvislosti so stratou Dr. Rongxiang Xu ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol ... dobe a jeho odhodlanie v oblasti vedy a ...
(Date:5/26/2015)... Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today announced ... its Board of Directors.  His appointment strengthens Fluorinov,s leadership ... accelerates its clinical development activities.  "On ... to welcome Luke to the Board of Directors.  Luke ... strength and success of multiple organizations," said Malik ...
Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... EPS increased 16.0 percent to $0.58 from $0.50 ... amortization of intangible assets from the 2003 spin-off, ... first-quarter 2008- Total net revenues increased 14.4 percent ... increased 21.0 percent to a record $2.3 billion- ...
... - Results to be Presented at World ... AB announced today that it has completed its open Phase ... nephropathy, a,glomerulonephritis leading to end-stage renal disease. Nefecon is an ... in the kidneys through suppression of the gut immune,system. , ...
... and safety agencies are unable to cope with the ... nanotechnology. The nation needs a new agency to address ... health and environmental impacts of the technically complex products ... landmark paper, Oversight of Next Generation Nanotechnology, J. Clarence ...
Cached Biology Technology:Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 2Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 3Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 4Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 5Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 6Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 7Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 8Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 9Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 10Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 11Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 12Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 13Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 14Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 15Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 16Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 17Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 18Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 19Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 20Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 21Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 22Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010 23Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 2Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R) 3Former EPA official calls for new environmental and consumer protection agency 2
... of several isoprostanes produced from arachidonic acid during ... in the rat. 8-iso PGE2 inhibits U-46619 or ... and 5 µM, respectively. When infused into the ... of 4 mg/kg/min, 8-iso PGE2 decreases the GFR ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: